STRIDE-10 Results Support Merck's 21-Valent Pneumococcal Conjugate Vaccine
The phase 3 STRIDE-10 trial evaluated the safety and immunogenicity of V116 in pneumococcal vaccine-naive adults 50 years of age and older.
Source: empr.com
Eliav Barr News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Eliav Barr. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Eliav Barr Today - Breaking & Trending Today
Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases Results build on the data supporting the clinical profile...
Source: marketscreener.com
FDA approves Merck's drug to treat rare, deadly lung disease
Merck bought the company developing the drug for $11.5 billion in 2021
Source: qz.com
FDA approves Merck's drug for rare, deadly lung condition
The Food and Drug Administration on Tuesday approved a drug from Merck designed to treat a progressive and life-threatening lung condition in a win for both the...
Source: nbcchicago.com
FDA Approves Merck's WINREVAIR, a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension
WINREVAIR on top of background therapy significantly improved exercise capacity and multiple important secondary outcome measures compared to background therapy alone
Source: dicardiology.com